Considering the dual impact of both cytoplasmic and exosomal forms of GP73 on the VEGFR2 signaling axis, investigating inhibitors that target GP73 represents a promising strategy to counteract angiogenesis within the TME of HCC. The gene discussed is GOLM1; the disease is hepatocellular carcinoma.